Psychedelics Financing

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items concerning the first two weeks of March 2024. See previous edition Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More. Research The...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) announced its financial results for the year ended December 31, 2023 along with a business update. Numbers: Cash and cash equivalents totaled $99.7 million by Dec. 31, 2023, an almost 30% reduction compared to the $142.1 million held by December 31, 2022...

Welcome to Benzinga's psychedelics headlines roundup. This is our pick of must-read news items concerning the last few days of January and the first two weeks of February 2024. See previous edition: Anti-inflammatory Effects, Global Drug Survey, ‘Synthetic Surprise,’ UK’s Harm...

Psychedelics biotech Seelos Therapeutics (NASDAQ: SEEL) announced the pricing of a new underwritten public offering for an estimated $5.5 million in gross proceeds. The offering is expected to close on or about Dec. 1, 2023. On Tuesday, Seelos shares’ closing price was at $2.35, and Wednesday...

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan Vivek Ramaswamy, who famously said he did not approve of Ohio’s cannabis initiative last week despite expressing support for federal legalization, is now saying that if elected he will...

The duo comprised of clinical-stage natural psilocybin biotech Psyence Group Inc. and special purpose acquisition company Newcourt Acquisition Corp (NASDAQ: NCAC) announced that the SEC made effective a Form F-4 registration statement for a new business on November 13.  Psyence Group...

Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? An average of 17 veterans committed suicide per day in 2020 according to the Dept of Veterans Affairs. The percentage of veterans from conflicts in the Middle East who have experienced PTSD is nearly triple the...

Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) has announced a new underwritten offering of 66.66 million units to one of its largest institutional shareholders as well as new institutional investors. Unit price set at $0.45, an approximate $30 million will be fully funded upon the...

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc...

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next MAPS Public Benefit Corporation (MAPS PBC), the nonprofit’s clinical-stage private arm, published new data from its second multi-site, ethno-racially diverse Phase 3 clinical study of MDMA-assisted...

Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly 19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). The considerably large acquisition puts Cybin in the limelight with credibility...

Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies Beckley Waves, a U.K.-based venture studio co-founded by "Queen of Psychedelics" Amanda Feilding with angel investors like FJ Labs, Courtney & Carter Reum, Joanne Wilson...

The Norrsken Foundation, a non-profit impact ecosystem “connecting founders with the capital, knowledge and network they need to make saving the world their business,” is launching a $3.22 (€3) million initiative to support Swedish startups developing psychedelic-assisted mental...

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE: CYBN) and UK-based Small Pharma (OTCMKTS: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and...

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials Starting this October, scientists at Imperial College London’s (ICL) Centre for Psychedelic Research will assess psilocybin-assisted therapy for gambling addiction in a government-funded study...